Get started
Live feed
·
PRReleasevia Quantisnow
CAMP4 Therapeutics Corporation logo

CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union

ByQuantisnow·Wall Street's wire, on your screen.
Stocks in this Quantisnow insight
Quantisnow market dataNASDAQ
CAMP4 Therapeutics Corporation logo
CAMP
CAMP4 Therapeutics Corporation
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Listed since
2024
Get push alerts for CAMP

Follow CAMP and get a push notification the moment its next story breaks.

Full CAMP profile on Quantisnow

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CAMP (CAMP4 Therapeutics Corporation) and more on Quantisnow.